Clinigen Group

Clinigen Group is a rapidly-growing specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of four synergistic businesses that provide medicines to patients with unmet need through clinical trials, licensed and unlicensed routes: Clinigen Clinical Trial Services (CTS) - The global leader in the specialist supply and management of quality-assured comparator drugs and other commercial medicines for patients in clinical trials. Cinigen is also the leading global patient access specialist working to provide ethical and compliant access to unlicensed medicines for healthcare providers and their patients with high unmet medical need: Idis Managed Access (MA) - Ethically manages early access to unlicensed investigational medicines on behalf of pharmaceutical and biotech companies. Idis Global Access (GA) - Enables access to post-approved medicines in regions where they are not commercially available but where there is a patient need. Clinigen Specialty Pharmaceuticals (SP) - Revitalizes essential hospital only medicines ensuring continuity of supply to hospital pharmacists, doctors and patients.
Company Growth (employees)
Type
Public
HQ
Burton Upon Trent, GB
Founded
2010
Size (employees)
465 (est)+200%
Clinigen Group was founded in 2010 and is headquartered in Burton upon Trent, GB

Clinigen Group Office Locations

Clinigen Group has an office in Burton upon Trent
Burton upon Trent, GB (HQ)
Clinigen, Pitcairn House, Crown Square, First Avenue
Show all (1)

Clinigen Group Financials and Metrics

Clinigen Group Financials

Clinigen Group's revenue was reported to be £302.3 m in FY, 2017 which is a 11% decrease from the previous period.
GBP

Revenue (FY, 2017)

302.3 m

Gross profit (FY, 2017)

122.7 m

Gross profit margin (FY, 2017), %

41%

Net income (FY, 2017)

3.8 m

EBITDA (FY, 2017)

44.8 m

EBIT (FY, 2017)

44.8 m

Market capitalization (31-Oct-2017)

1.4 b

Closing share price (31-Oct-2017)

11.7

Cash (30-Jun-2017)

27.8 m

EV

1.3 b
Clinigen Group's current market capitalization is £1.4 b.
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.5 m5.1 m35 m82.1 m122.6 m126.6 m184.4 m339.9 m302.3 m

Revenue growth, %

3%46%84%

Cost of goods sold

1.8 m2.2 m19.5 m53.1 m87.5 m85.4 m130.7 m243.8 m179.6 m

Gross profit

661 k2.9 m15.5 m29 m35.1 m41.2 m53.7 m96.1 m122.7 m
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

328.8 k156.4 k4.3 m6.6 m11.3 m16.2 m5.7 m13.5 m3.8 m

Cash From Operating Activities

997.4 k9.1 m12.6 m4 m18.3 m19.3 m13.1 m42.1 m46.1 m

Dividends Paid

781 k495 k2.5 m2.6 m4.1 m4.9 m

Cash From Financing Activities

(846 k)(4.5 m)6.5 m13.8 m181.3 m(12.3 m)(37.8 m)
    GBPY, 2017

    EV/EBITDA

    29.9 x

    EV/EBIT

    29.9 x

    EV/CFO

    29.1 x

    Revenue/Employee

    650.1 k

    Debt/Equity

    0.1 x

    Financial Leverage

    1.8 x
    Show all financial metrics

    Clinigen Group Operating Metrics

    Clinigen Group's Units Shipped was reported to be 4 m in FY, 2016
    FY, 2016

    Countries

    43

    Units Shipped

    3.97 m
    Show all operating metrics

    Clinigen Group Market Value History

    Clinigen Group Revenue Breakdown

    Clinigen Group's Web-traffic and Trends

    Clinigen Group Online and Social Media Presence

    Clinigen Group Company Life and Culture

    You may also be interested in